Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHA-ORBIT phase 3 trial of navenibart for hereditary angioedema
jRCT2031250452Phase 3Active, not recruiting
- Sponsor
- Astria Therapeutics
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of navenibart in hereditary angioedema (HAE) (4 arms), sponsored by Astria Therapeutics. Primary endpoint: Number of time-normalized investigator-confirmed hereditary angioedema attacks during the 6-month treatment period. Started Oct 2025; status: active, not recruiting.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2031250452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250452.